We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Bacterial resistance
- Targets for control
- MRSA
- Community-acquired MRSA
- Community MRSA in USA
- Control measures of MRSA (1)
- Community MRSA in Denmark (1)
- Community MRSA in Denmark (2)
- Control measures of MRSA (2)
- Tuberculosis
- Resistant TB in USA
- Control of tuberculosis
- ESBL
- Control measures of ESBL
- Vancomycin resistant enterococci (VRE)
- Pneumococci
- Primary care
- Ciprofloxacin resistant N. gonorrhoeae - prevalence
- Antimicrobial prescribing practice 2003 to 2007
- Public attitudes
- Acinetobacter baumannii (1)
- Acinetobacter baumannii (2)
- Acinetobacter control
- Promote compliance
- Conclusion
- Thank you
- References
Topics Covered
- Risk factors and control of multi-resistant pathogens
- Community-acquired MRSA
- Multi-drug resistant tuberculosis
- Extended spectrum beta-lactamase producing Gram negative bacteria
- Vancomycin resistant enterococci
- Antibiotic stewardship in primary care
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Wilson, P. (2015, July 24). Controlling antibiotic resistance in the community [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/AQZZ3461.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Peter Wilson has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Microbiology
Transcript
Please wait while the transcript is being prepared...
0:00
This is Doctor P Wilson Consultant Microbiologist at University College London Hospitals.
I'm going to talk about Controlling Antibiotic Resistance in the community.
I've around 20 years experience looking after
the Camden and Islington Primary Care Trusts
with regards to both antibiotics and infection control.
0:24
Bacterial resistance is a worldwide problem although mutation itself is quite rare.
Most of this increasing difficulty is due to an increased use of antibiotics.
The more we use, the more infection becomes resistant.
Suboptimal dosing usually due to
poor compliance in a part of the patient is also a real problem.
And a further contributor is the use of growth promoting antibiotics in animals.
For example, Ava Paulsen has been used for many years at least until
the last couple of years to make the weight of chickens greater.
Surveillance is useful because it can tell us
how much bacteria resistance there is in a local community.
And we can feedback to the clinicians
what their appropriate use of antibiotics in the community should be.
And thereby, giving some measure of control over bacterial resistance.
1:25
The targets for control are
Methicillin-resistant Staphylococcus aureus with which we're all familiar.
The extended spectrum beta-lactamase producers,
which are gram negative rods present in the gut
but a common cause of complicated Urinary Tract Infection.
Multidrug resistant tuberculosis, which is prevalent in a low level
in the community and is a problem both for the staff as well as the patients.
Vancomycin resistant enterococci, they are present in the gut floor of
the normal population but are a particular issue with treatment of leukemic patients.
Pneumococci are showing more and more resistance
to penicillin particularly those strains coming in from Spain.
And Neisseria gonorrhoeae increasing levels of
Ciprofloxacin resistance particularly when those strains are imported from the far East.
Finally, Acinetobacter Baumannii has been a major problem in hospitals
already and is starting to be seen in the community.